In this article, we will look at the 5 Stocks Investors Are Watching Closely This Week. For a deeper discussion and an extended list, please see 10 Stocks Investors Are Watching Closely This Week
Photo by Tima Miroshnichenko on Pexels
5. Wix.com Ltd. (NASDAQ:WIX)
Wix saw its share prices jump by 33.25 percent week-on-week after reporting a 13-percent growth in revenues last year and announcing an aggressive plan to mostly complete its $2 billion share buyback program this year.
Earlier in the week, Wix.com Ltd. (NASDAQ:WIX) said that its revenues soared to $1.99 billion last year from $1.76 billion in 2024, thanks to a double-digit growth in revenues from creative subscriptions and business solutions.
However, net income still decreased by 63 percent to $50.6 million from $138.3 million year-on-year.
In the fourth quarter alone, Wix.com Ltd. (NASDAQ:WIX) said that revenues surged by 14 percent to $524.3 million from $460.4 million. However, it swung to a net loss of $40.2 million from a $48 million net income in the same period.
For this year, the company is targeting revenues to grow by mid-teens in both the first quarter and full-year period.
Bookings are also expected to grow mid-teens in the full-year period.
Following the results, Wix.com Ltd. (NASDAQ:WIX) announced plans to go aggressive and quick on its share buyback program this year, as it eyes to already complete majority of its $2 billion share repurchase authorization.
As of end-2025, the company has already bought back $575 million worth of shares.
4. Tango Therapeutics Inc. (NASDAQ:TNGX)
Tango Therapeutics soared by 52.15 percent week-on-week, as investors took heart from a flurry of positive developments, including a “buy” recommendation for its stock and the start of a series of clinical trials for its pancreatic cancer treatment candidate vopimetostat..
In a market report during the week, investment firm Stifel reaffirmed its “buy” recommendation and $15 price target for Tango Therapeutics Inc. (NASDAQ:TNGX), following improvements in its earnings performance last year, having narrowed its net losses by 22 percent to $101.59 million from $130.3 million in 2024.
Total revenues, on the other hand, jumped by 48.3 percent to $62.38 million from $42.07 million year-on-year.
However, net loss in the fourth quarter widened by 26 percent to $38.7 million from $30.76 million, having earned no revenues during the period, versus a $5.4 million revenue in the same period a year earlier.
For this year, Tango Therapeutics Inc. (NASDAQ:TNGX) is targeting to kick off a number of clinical trials to test its drug candidate vopimetostat in combination with multiple inhibitors for the treatment of pancreatic cancer.
It recently clinched a partnership with Erasca to jointly study the combination of vopimetostat with ERAS-0015 in treating pancreatic cancer.
3. Amprius Technologies Inc. (NYSE:AMPX)
Amprius Technologies rallied by 52.19 percent week-on-week and hit a new all-time high after a flurry of positive developments, including analyst upgrades and a highly optimistic outlook for the year.
In separate market reports, Cantor Fitzgerald and Craig-Hallum raised their price targets for Amprius Technologies Inc. (NYSE:AMPX) to $20 and $21, from $16 and $17, respectively.
Cantor issued an “overweight” rating while Craig-Hallum assigned a “buy” recommendation.
The coverage followed Amprius Technologies Inc.’s (NYSE:AMPX) highly optimistic outlook for this year, having targeted a 71 percent growth in revenues for the full-year period.
According to the company, it is setting its sights on revenues of $125 million this year, versus $73 million last year. If realized, it would end the year with a 417-percent revenue jump in just two years, versus only $24.17 million in 2024.
However, it expects to remain at a net loss of $8 million in 2026, albeit an 82-percent expected improvement from $44 million in net losses last year.
“2025 marked a year of meaningful commercial progress, as we expanded our customer base to over 550, increased revenue by over 3x, and advanced the adoption of our silicon anode batteries across multiple end markets,” Amprius Technologies Inc. (NYSE:AMPX) CEO Tom Stepien said.
“Growing demand from existing customers, new program wins, and improved execution across our manufacturing partners drove strong momentum throughout the year. Looking ahead to 2026, we plan to leverage our enhanced supply chain to scale production and meet accelerating market demand, supporting continued accretive growth,” he added.
2. Sable Offshore Corp. (NYSE:SOC)
Sable Offshore skyrocketed by 74 percent week-on-week, as investors placed bets following an executive department’s opinion confirming that President Donald Trump could override conflicting federal laws that prevent the listed firm from conducting full operations at its California pipeline system.
Thomas Elliot Gaiser, assistant attorney general for the Office of Legal Counsel of the Department of Justice, said that a presidential order could preempt California laws currently impeding Sable Offshore Corp. (NYSE:SOC) from fully operating its Las Flores onshore pipeline.
Operations at its offshore unit, Santa Ynez, have already started in May, but Sable Offshore Corp. (NYSE:SOC) remains unable to sell or transport hydrocarbons through its Las Flores unit pending court approval.
“We conclude that it (a presidential order) would. An order issued as an exercise of congressionally delegated authority or the President’s constitutional powers has the force of federal law under the Supremacy Clause and may preempt contrary state law,” he said.
“Because the DPA (Defense Production Act) authorizes the President to order certain actions that may otherwise be prohibited by state law, an order issued pursuant to the DPA could preempt those laws expressly or by conflict,” he noted.
The statement sparked renewed optimism and buying appetite for Sable Offshore Corp. (NYSE:SOC), which has been battling for the revival of the pipeline for 10 years since it was ordered shut in June 2015 following a leak that caused a major oil spill.
1. Day One Biopharmaceuticals Inc. (NASDAQ:DAWN)
Day One soared by 100 percent week-on-week, as investors gobbled up its shares following an acquisition that it is set to be taken private and tendered at a 68 percent upside.
In a statement earlier in the week, Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) said that it is set to be acquired by France-based Servier for a transaction worth $2.5 billion.
Under the agreement, all issued and outstanding shares of Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) will be tendered at $21.50 apiece, or a 68 percent upside from the $12.78 closing price prior to the announcement.
According to the companies, the transaction is expected to be closed in the second quarter of the year, subject to customary closing conditions, including shareholder approval.
“Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies make it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life-threatening diseases,” Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) CEO Jeremy Bender said.
“Joining Servier represents a unique opportunity to extend the reach of our science and our lead program in pediatric low‑grade glioma. Importantly, Servier’s dedication to the rare disease community preserves the patient‑first mindset that has defined our company since the beginning and has driven our deep commitment to the communities we serve,” he noted.
While we acknowledge the potential of DAWN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DAWN and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
